Skip to main content

Table 4 Comparison of cost trajectory groups

From: Going beyond the mean: economic benefits of myocardial infarction secondary prevention

Prophylactic medication

Traj. Group

Full population

N compliant (%)

Multivariable

RRR [95%CI]

p-value

Not pre-exposed

N compliant (%)

Multivariable

RRR [95%CI]

p-value

4-class combination

(main analysis)

1

478/1302 (36.7)

Ref.

0.0191

192/429 (44.8)

Ref.

0.5253

2

71/245 (29.0)

0.89 [0.65; 1.22]

 

25/62 (40.3)

0.84 [0.47; 1.50]

 

3

22/87 (25.3)

0.71 [0.42; 1.21]

 

8/14 (57.1)

2.29 [0.67; 7.88]

 

4

3/31 (9.7)

0.20 [0.06; 0.71]

 

5/12 (41.7)

0.81 [0.24; 2.77]

 

3- & 4-class combinations

(sensitivity analysis)

1

353/1302 (27.1)

Ref.

0.5457

134/429 (31.2)

Ref.

0.4777

2

65/245 (26.5)

1.07 [0.77; 1.48]

 

20/62 (32.3)

1.19 [0.65; 2.16]

 

3

28/87 (32.2)

1.44 [0.88; 2.34]

 

2/14 (14.3)

0.38 [0.07; 1.95]

 

4

7/31 (22.6)

0.96 [0.40; 2.34]

 

4/12 (33.3)

1.24 [0.34; 4.46]

 
  1. Distribution of compliers and non-compliers across the four trajectory groups (Fig. 4). This analysis investigates whether persons complying with a specific prevention drug combination have a higher probability of being included in the most favorable cost trajectory 1 (used as a reference). A multinomial logistic regression was used to test this hypothesis. The model was estimated for compliance status to a specific drug (main variable of interest shown in the table) and confounder adjustments as described in the methods section (coefficients not shown). P-values < 0.05 are highlighted in bold
  2. Abbreviations: RRR multivariable Relative Risk Ratios, 95% CI 95% Confidence Intervals, Traj Trajectory